Phase II Study of the combination of Elotuzumab with Lenalidomide as Maintenance Therapy post Autologous Stem Cell Transplant in Patients with Multiple Myeloma
Phase of Trial: Phase II
Latest Information Update: 12 Dec 2017
At a glance
- Drugs Elotuzumab (Primary) ; Lenalidomide (Primary) ; Dexamethasone; Diphenhydramine; Famotidine
- Indications Multiple myeloma
- Focus Therapeutic Use
- 12 Dec 2017 Preliminary results (n=55) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 26 May 2017 Planned End Date changed from 1 Apr 2018 to 1 Apr 2019.
- 26 May 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2019.